Trevi Therapeutics
TRVI
Market cap $607M

6.28 USD

+0.27

4.49%

At close Apr 2, 4:00 PM EDT

1 day

4.49%

5 days

-2.94%

1 month

47.42%

3 months

44.04%

6 months

96.87%

Year to date

44.04%

1 year

94.43%

5 years

136.09%

10 years

-20.41%

About: Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Employees: 26

Healthcare Drug Manufacturers - General

Funds holding %

of 7,398 funds

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

271% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 7

96% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 24

69% more capital invested

Capital invested by funds: $194M [Q3] → $329M (+$135M) [Q4]

16% more funds holding

Funds holding: 93 [Q3] → 108 (+15) [Q4]

8.7% more ownership

Funds ownership: 80.2% [Q3] → 88.91% (+8.7%) [Q4]

13% less call options, than puts

Call options by funds: $927K | Put options by funds: $1.06M

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$12.50

99%

upside

Avg. target

$21

236%

upside

High target

$29

362%

upside

6 analyst ratings

6 positive

100%

0 neutral

0 negative

B. Riley Securities Mayank Mamtani 14% 1-year accuracy 3 / 22 met price target	218%upside $20	Buy Reiterated	19 Mar 2025
Needham Serge Belanger 39% 1-year accuracy 47 / 121 met price target	282%upside $24	Buy Maintained	19 Mar 2025
D. Boral Capital Jason Kolbert 27% 1-year accuracy 88 / 330 met price target	234%upside $21	Buy Maintained	19 Mar 2025
HC Wainwright & Co. Oren Livnat 50% 1-year accuracy 25 / 50 met price target	99%upside $12.50	Buy Reiterated	19 Mar 2025
Oppenheimer Leland Gershell 35% 1-year accuracy 17 / 49 met price target	218%upside $20	Outperform Maintained	11 Mar 2025

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about TRVI published over the past 30 days

Neutral

Seeking Alpha

2 weeks ago

Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Jennifer Good - Co-Founder, President and Chief Executive Officer Lisa Delfini - Chief Financial Officer Conference Call Participants Faisal Khurshid - Leerink Partners Mayank Mamtani - B. Riley Annabel Samimy - Stifel Leland Gershell - Oppenheimer Serge Belanger - Needham & Company Ryan Deschner - Raymond James Brandon Folkes - Rodman & Renshaw Christian Cubides - Clear Street Operator Good afternoon and welcome to the Trevi Therapeutics Fourth Quarter and Year End 2024 Earnings Conference Call.

Neutral

PRNewsWire

2 weeks ago

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and RCC Completed enrollment in the Phase 2b CORAL trial in IPF patients with chronic cough in February 2025, with topline data expected in the second quarter of 2025 Announced positive outcome from sample size re-estimation in the Phase 2b CORAL trial, resulting in no change to study sample size Ended 2024 with $107.6 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn.

Neutral

PRNewsWire

3 weeks ago

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.

Positive

Zacks Investment Research

3 weeks ago

TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study

Data from a mid-stage study shows that treatment with Trevi's experimental drug reduced patients' 24-hour cough frequency by 57% over placebo.

Positive

Benzinga

3 weeks ago

Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps

On Monday, Trevi Therapeutics, Inc. TRVI reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) for the treatment of patients with refractory chronic cough (N=66).

Neutral

PRNewsWire

3 weeks ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Haduvio met the primary endpoint with a statistically-significant reduction (p

$Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$

Neutral

PRNewsWire

3 weeks ago

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn.

$Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$